Skip to search formSkip to main contentSkip to account menu

ECOG Performance Status 0

Known as: ECOG 0 
Fully active, able to carry on all pre-disease performance without restriction.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Abstract P5-21-24: Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2– advanced breast cancer enrolled in an…
Background: The objective of this study was to evaluate treatment patterns and clinical outcomes among patients who received… 
2018
2018
Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival… 
2014
2014
Prognostic significance of the neutrophil-lymphocyte ratio (NLR) in phase 1 clinical trial patients.
3037 Background: Inflammation has a critical role in the pathogenesis and progression of tumours. A high pre-treatment NLR has… 
2013
2013
Abstract P2-15-02: Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients
Purpose: Trastuzumab (T; Roche) is part of the standard treatment in patients (pts) of any age with early stage, HER2+ breast… 
2011
2011
PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a…
Background: First-line treatment of HER2−negative LR/MBC with paclitaxel (T) and bevacizumab (A) has demonstrated improved… 
2010
2010
PRECISION V: Randomisierte Phase II-Studie mit Drug Eluting Beads (DEB) zur Behandlung des hepatozelluläre Karzinoms (HCC) mittels transarterieller Chemoemblisation [PRECISION V: Randomized Phase II…
Zielsetzung: Vergleich von Drug Eluting Bead (DEB)-TACE mit konventioneller TACE bei der Behandlung von ,,intermediate stage-HCC… 
2010
2010
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
7547 Background: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with… 
2010
2010
Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.
3018 Background: AMG 479, a fully human monoclonal antibody antagonist of IGF1R, showed activity in early clinical trials and… 
2009
2009
Cardiac Safety Results of a Phase II Trial of Adjuvant Docetaxel/Cyclophosphamide Plus Trastuzumab (Her TC) in HER2+ Early Stage Breast Cancer Patients.
Background: Docetaxel/cyclophosphamide (TC) has superior activity to doxorubicin/cyclophosphamide (AC) in the adjuvant treatment… 
2009
2009
Preliminary toxicity results of a phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab in HER2+ early stage breast cancer patients.
Abstract #2111 Background: Docetaxel/cyclophosphamide (TC) has demonstrated superior activity to doxorubicin/cyclophosphamide (AC…